Davis David A, Shrestha Prabha, Yarchoan Robert
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Glob Health Med. 2024 Oct 31;6(5):282-284. doi: 10.35772/ghm.2024.01069.
In this editorial, we highlight the potential use of inhibitors of hypoxia-inducible factors (HIFs) for the use in Kaposi's sarcoma associated herpesvirus (KSHV) (also known as human herpesvirus-8) related malignancies. The past 20 years has accumulated detailed knowledge of the role of these factors in ensuring the maintenance of the KSHV in infected cells, in aiding the growth of the virus infected cells and aiding in the spread of virus from infected cells by inducing lytic reactivation. Today, a wide range of inhibitors for HIFs are currently being clinically evaluated for use in treating a variety of cancers. We discuss the current state of this research area as it relates to KSHV malignancies and describe pre-clinical and clinical evidence of drugs that target HIF to back up the idea that these inhibitors could be a novel way to treat KSHV related diseases.
在这篇社论中，我们强调了缺氧诱导因子（HIFs）抑制剂在卡波西肉瘤相关疱疹病毒（KSHV，也称为人类疱疹病毒8型）相关恶性肿瘤中的潜在应用。在过去20年里，我们已经积累了关于这些因子在确保KSHV在受感染细胞中维持、帮助病毒感染细胞生长以及通过诱导裂解再激活帮助病毒从受感染细胞中传播方面所起作用的详细知识。如今，多种HIFs抑制剂正在进行临床评估，用于治疗各种癌症。我们讨论了该研究领域与KSHV恶性肿瘤相关的当前状况，并描述了靶向HIF的药物的临床前和临床证据，以支持这些抑制剂可能是治疗KSHV相关疾病的新方法这一观点。
